MeritValue

Petros Pharmaceuticals, Inc.

PTPIdata completeness 63%6 fiscal years on file
The thesis, from the filings

Petros Pharmaceuticals, Inc. earns about -37% on equity, but has diluted owners by 2477% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$7.81M1$5.99M2$5.82M3$5.11M3—
Net income−$8.99M4−$20M5−$8.16M6−$14.3M7$1.91M7
Operating cash flow−$11.9M8−$12.8M9−$7.63M10−$2.6M11−$6.73M11
Capital expenditure———$24,58712—
Free cash flow (derived)———−$2.63M11—
Total debt—————
Cash & equivalents$23.8M13$9.43M13$13.3M14$1.72M15$5.14M15
Diluted shares1.1M2.1M2.2M321,04228.1M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
$1.02
your share of equity
Profit it earned you last year
$0.68
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on $1.02 of net worth that earned you $0.68 last year.

iii. Is this a good business?
Moat signal · return on equity
-37% avg · 5y
FY21 -25%FY22 -120%FY23 -68%FY24 —FY25 67%

It earned an average -37% on equity over 5 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →
Management signal · capital allocation
+2477% shares · 5y

Share count is up 2477% over 5 years — owners have been diluted. Worth asking what they got for it.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 2 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 2 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2021-12-31 · accession 0001410578-23-000575 (RevenueFromContractWithCustomerExcludingAssessedTax)
  2. 10-K · period ending 2022-12-31 · accession 0001410578-24-000401 (RevenueFromContractWithCustomerExcludingAssessedTax)
  3. 10-K · period ending 2023-12-31 · accession 0001410578-25-000579 (RevenueFromContractWithCustomerExcludingAssessedTax)
  4. 10-K · period ending 2021-12-31 · accession 0001410578-23-000575 (NetIncomeLoss)
  5. 10-K · period ending 2022-12-31 · accession 0001410578-24-000401 (NetIncomeLoss)
  6. 10-K · period ending 2023-12-31 · accession 0001410578-25-000579 (NetIncomeLoss)
  7. 10-K · period ending 2024-12-31 · accession 0001104659-26-043822 (NetIncomeLoss)
  8. 10-K · period ending 2021-12-31 · accession 0001410578-23-000575 (NetCashProvidedByUsedInOperatingActivities)
  9. 10-K · period ending 2022-12-31 · accession 0001410578-24-000401 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2023-12-31 · accession 0001410578-25-000579 (NetCashProvidedByUsedInOperatingActivities)
  11. 10-K · period ending 2024-12-31 · accession 0001104659-26-043822 (NetCashProvidedByUsedInOperatingActivities)
  12. 10-K · period ending 2024-12-31 · accession 0001410578-25-000579 (PaymentsToAcquirePropertyPlantAndEquipment)
  13. 10-K · period ending 2021-12-31 · accession 0001410578-23-000575 (CashAndCashEquivalentsAtCarryingValue)
  14. 10-K · period ending 2023-12-31 · accession 0001410578-25-000579 (CashAndCashEquivalentsAtCarryingValue)
  15. 10-K · period ending 2024-12-31 · accession 0001104659-26-043822 (CashAndCashEquivalentsAtCarryingValue)